11.07.18|Lilach BaumerMylan has achieved a 15%-20% market share in the U.S. since launching its generic version in late 2017 with a monthly price tag of $5,000, compared to Teva's $5,800
31.10.17|Lilach BaumerMapi Pharma announced a successful phase II clinical trial for its Copaxone equivalent GA Depot
More stories in CTech
